Perimeter Medical Imaging AI (PINK) AI Stock Analysis

• Market Cap: C$24.31M
• Dividend Yield: N/A
• Average Volume (3M): 87.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.02
• Revenue Growth: 113.85%
• EPS Growth: 11.38%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Devices
• EPS (TTM): -0.07
• Shares Outstanding: 93,513,840
• 10 Day Avg. Volume: 158,666
• 30 Day Avg. Volume: 87,720
• PEG Ratio: N/A
• Price to Book (P/B): 1.79
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.95
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$3.00
• Price Target Upside: 1053.85% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 50 Neutral
• Price Target: ―

Perimeter Medical Imaging AI is positioned in a growth phase with strong revenue increases and promising clinical advancements towards FDA approval. However, persistent net losses, cash flow constraints, and bearish technical indicators pose significant challenges. The valuation remains unattractive, but recent strategic corporate events offer potential for future expansion.

Perimeter Medical Imaging AI Business Overview & Revenue Model

Company Description

Perimeter Medical Imaging AI, Inc., a medical technology company, develops and commercializes advanced imaging tools that allow surgeons, radiologists, and pathologists to visualize microscopic tissue structures during a clinical procedure. The company offers an optical coherence tomography (OCT) imaging system provides clinicians with cross-sectional of tissues down to 2 mm dept. This OCT imaging system consists of S-series OCT, B-series OCT, and OCT imaging console. It also offers ImgAssist, an artificial intelligence technology that enhances the efficiency of image review and be an additional powerful tool when combined with Perimeter OCT to aid physicians with real-time margin visualization and assessment to improve surgical outcomes for patients and reducing the likelihood of needing additional surgeries. In addition, the company offers proprietary image library and consumable specimen containers to hospitals and cancer surgery centers. Perimeter Medical Imaging AI, Inc. was founded in 2013 and is headquartered in Toronto, Canada.

How the Company Makes Money

Perimeter Medical Imaging AI makes money primarily through the sale and leasing of its imaging devices to hospitals and surgical centers. The company also generates revenue from service agreements, maintenance contracts, and by offering training and support for its technology. Additionally, Perimeter may engage in partnerships with healthcare providers and research institutions to expand the application of its technology and drive adoption, which can further contribute to revenue through collaborative agreements and research grants. Key revenue streams include direct sales of imaging devices, recurring revenue from ongoing service and maintenance, and strategic partnerships that enhance their market presence.

Perimeter Medical Imaging AI Financial Statement Overview

Summary

Perimeter Medical Imaging AI is in a growth phase with increasing revenues but faces significant financial challenges, notably in profitability and cash flow management. The company has a strong equity base with minimal debt, providing some financial stability, but needs to address its ability to generate positive cash flow and achieve profitability to ensure long-term sustainability.

Income Statement

Perimeter Medical Imaging AI has shown a significant increase in revenue over the years, although it remains relatively low. The gross profit margin for the TTM is healthy at 59.45%, indicating efficient cost management relative to revenue. However, the company continues to sustain substantial losses, reflected in a negative net profit margin of -2477.50% and negative EBIT and EBITDA margins, indicating challenges in achieving operational profitability.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.01, suggesting minimal leverage and low financial risk. However, the equity ratio is 81.74%, indicating strong reliance on equity financing. The negative net income affects the return on equity, which is also negative, suggesting inefficient use of shareholder funds to generate returns.

Cash Flow

Perimeter Medical Imaging AI faces challenges with negative operating and free cash flows, showing a decline in cash generation from operations. The free cash flow growth rate remains negative, indicating ongoing cash flow constraints. The ratios of operating and free cash flow to net income are both negative, reflecting difficulties in converting earnings into cash.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
625.73K	403.53K	132.77K	11.34K	0.00	0.00
	Gross Profit
372.07K	206.42K	100.63K	5.04K	-47.57K	-51.84K
	EBIT
-18.88M	―	-16.12M	-16.05M	-11.67M	-13.02M
	EBITDA
-15.46M	-17.92M	-11.72M	-15.95M	-6.11M	-7.01M
	Net Income Common Stockholders
-15.50M	-18.94M	-3.59M	-16.76M	-8.00M	-10.50M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.21M	18.43M	28.44M	5.14M	11.70M	1.21M
	Total Assets
2.55M	27.09M	34.60M	9.98M	13.16M	2.55M
	Total Debt
14.21M	192.89K	325.68K	441.17K	400.81K	14.21M
	Net Debt
13.00M	-18.18M	-28.11M	-4.28M	-9.62M	13.00M
	Total Liabilities
19.03M	7.10M	8.49M	2.56M	2.40M	19.03M
	Stockholders Equity
-16.47M	15.06M	26.11M	7.42M	10.76M	-16.47M
Cash Flow		Free Cash Flow
-16.01M	-15.17M	-13.86M	-16.03M	-8.26M	-5.83M
	Operating Cash Flow
-15.64M	-14.70M	-11.87M	-13.91M	-8.26M	-5.79M
	Investing Cash Flow
48.01K	206.01K	-1.75M	-1.45M	7.24M	-46.95K
	Financing Cash Flow
7.07M	234.47K	40.28M	10.06M	9.84M	5.20M

Perimeter Medical Imaging AI Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PINK, the sentiment is Negative. The current price of 0.26 is below the 20-day moving average (MA) of 0.39, below the 50-day MA of 0.42, and below the 200-day MA of 0.47, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 25.15 is Positive, neither overbought nor oversold. The STOCH value of 1.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:PINK.

Perimeter Medical Imaging AI Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
QIPT	59 Neutral	C$105.13M	―	-8.34%	―	0.69%	-95.27%
ASG	55 Neutral	C$23.81M	―	-23.87%	―	18.97%	17.57%
PRN	54 Neutral	C$219.39M	―	-66.14%	―	51.21%	15.33%
Sector *	53 Neutral	$5.20B	3.32	-45.04%	2.84%	16.81%	-0.31%
PINK	50 Neutral	C$24.31M	―	-163.62%	―	113.85%	11.38%
TLT	49 Neutral	C$52.03M	―	-291.48%	―	-8.63%	7.04%
VPT	44 Neutral	C$17.95M	―	207.08%	―	280.56%	-7.28%

Perimeter Medical Imaging AI Corporate Events

HonorHealth Adopts Perimeter’s Advanced Imaging Technology in Arizona

Perimeter Medical Imaging AI announced that HonorHealth is the first healthcare system in Arizona to implement its S-Series OCT technology, enhancing surgical decision-making with real-time, high-resolution imaging of tissue margins. This deployment marks a significant step in Perimeter’s nationwide expansion, increasing access to their technology in a major metropolitan area and reflecting the growing demand for improved surgical outcomes.

Spark’s Take on TSE:PINK Stock

According to Spark, TipRanks’ AI Analyst, TSE:PINK is a Neutral.

Perimeter Medical Imaging AI shows strong revenue growth and promising developments in product approval, positioning it for future expansion. However, persistent net losses, cash flow issues, and bearish technical trends pose significant challenges. The stock’s valuation is unattractive due to negative profitability. While the company is in a pivotal growth phase with potential regulatory milestones ahead, financial and operational hurdles must be overcome to enhance investor confidence.

To see Spark’s full report on TSE:PINK stock, click here.

Perimeter Medical Imaging AI to Present at 2025 Healthcare Investor Conference

Perimeter Medical Imaging AI announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference, where it will present updates on its business. This participation underscores Perimeter’s ongoing efforts to enhance its industry presence and communicate its technological advancements, potentially impacting its market positioning and stakeholder engagement.

Spark’s Take on TSE:PINK Stock

According to Spark, TipRanks’ AI Analyst, TSE:PINK is a Neutral.

Perimeter Medical Imaging AI shows strong revenue growth and promising developments in product approval, positioning it for future expansion. However, persistent net losses, cash flow issues, and bearish technical trends pose significant challenges. The stock’s valuation is unattractive due to negative profitability. While the company is in a pivotal growth phase with potential regulatory milestones ahead, financial and operational hurdles must be overcome to enhance investor confidence.

To see Spark’s full report on TSE:PINK stock, click here.

Perimeter Medical Imaging AI Announces Public Offering to Boost Commercialization Efforts

Perimeter Medical Imaging AI, Inc. announced a proposed public offering of units, consisting of common shares and purchase warrants, to raise funds for the commercialization of its technology, clinical evidence establishment, and product development. The offering, expected to close by the end of April 2025, will be conducted on a ‘best efforts’ basis with A.G.P. Canada Investments ULC as the agent, and aims to strengthen the company’s market position and operational capabilities.

Perimeter Medical Imaging AI Reports Strong 2024 Growth and Advances B-Series OCT Development

Perimeter Medical Imaging AI reported significant financial growth in 2024, with a 303% increase in Q4 revenues compared to the previous year, driven by the adoption of its S-Series OCT systems. The company is advancing its B-Series OCT system, having successfully completed a pivotal trial for breast-conserving surgeries and submitted a PMA application to the FDA. This progress positions Perimeter for further expansion and potential regulatory approval, which could enhance its market position and impact stakeholders positively.

Perimeter Medical Imaging AI to Announce 2024 Financial Results

Perimeter Medical Imaging AI announced it will release its fourth quarter and full year 2024 financial results on March 26, 2025, followed by a conference call to discuss the outcomes and provide a corporate update. This announcement is significant as it may impact the company’s operations and industry positioning, especially considering its ongoing clinical trials and the potential market introduction of its next-generation imaging technology.

Perimeter Medical Imaging AI Submits FDA Application for Advanced Imaging System

Perimeter Medical Imaging AI has submitted a Premarket Approval application to the FDA for its B-Series OCT system with ImgAssist AI 2.0, aimed at improving outcomes in breast-conserving surgeries. The pivotal trial showed significant results in reducing residual cancer during surgery, suggesting potential widespread adoption among breast cancer surgeons if approved, marking a significant milestone for the company’s operations and industry positioning.

Perimeter Medical’s Pivotal Trial Results to be Presented at ASBrS 2025

Perimeter Medical Imaging AI announced that its pivotal trial results for the B-Series OCT with ImgAssist AI 2.0 will be presented at the 2025 Annual Meeting of the American Society of Breast Surgeons. The trial showed a statistically significant reduction in residual cancer during surgery, supporting the company’s efforts to gain FDA approval for their next-generation imaging system. This development could enhance the adoption of their technology, providing surgeons with improved tools for breast cancer surgery.

Perimeter Medical Imaging AI to Trade on OTCQX, Eyes U.S. Expansion

Perimeter Medical Imaging AI announced that its common shares will begin trading on the OTCQX Best Market, enhancing its visibility and efforts to expand its U.S. shareholder base. This move follows positive results from a pivotal study supporting the company’s FDA premarket approval submission for its B-Series OCT with ImgAssist AI, which demonstrated significant improvements in surgical outcomes, potentially reducing the need for reoperations.